Ozempic vs Wegovy

Overview

Ozempic and Wegovy both contain the same active ingredient: semaglutide. The key difference is their FDA-approved indications and dosing. Ozempic is approved for type 2 diabetes, while Wegovy is approved for chronic weight management.

This is not a comparison of different drugs—it’s understanding when each brand is appropriately prescribed.

Key Facts

Aspect	Ozempic	Wegovy
Active Ingredient	Semaglutide	Semaglutide
Manufacturer	Novo Nordisk	Novo Nordisk
FDA Approval	2017 (Type 2 Diabetes)	2021 (Obesity)
Primary Indication	Glycemic control	Weight management

Same Drug, Different Approvals

Why Two Brands?

Pharmaceutical companies often pursue separate regulatory approvals for different indications. Each indication requires its own clinical trial program demonstrating safety and efficacy for that specific use.

Semaglutide development pathway:

1. 2017: Ozempic approved for T2D based on SUSTAIN trials
2. 2021: Wegovy approved for obesity based on STEP trials
3. 2024: Wegovy expanded for cardiovascular risk reduction (SELECT trial)

Indication Differences

Ozempic (Type 2 Diabetes)

FDA-approved for:

• Improve glycemic control in adults with type 2 diabetes
• Reduce risk of major adverse cardiovascular events in adults with T2D and established cardiovascular disease

Not approved for:

• Weight management (as primary indication)
• Type 1 diabetes
• Pediatric use

Wegovy (Chronic Weight Management)

FDA-approved for:

• Adults with BMI ≥30 (obesity)
• Adults with BMI ≥27 with weight-related comorbidity (hypertension, T2D, dyslipidemia)
• Adolescents aged 12+ with obesity
• Cardiovascular risk reduction in adults with obesity and CVD (SELECT trial)

Requires:

• Reduced-calorie diet
• Increased physical activity

Clinical Trial Evidence

Ozempic Trials (SUSTAIN Program)

Trial	Focus	Key Result
SUSTAIN 1-5	Efficacy vs comparators	A1C reduction 1.0-1.8%
SUSTAIN 6	Cardiovascular outcomes	26% MACE reduction
SUSTAIN 7	Head-to-head vs dulaglutide	Superior A1C reduction

Wegovy Trials (STEP Program)

Trial	Focus	Key Result
STEP 1	Obesity without diabetes	-14.9% weight loss
STEP 2	Obesity with T2D	-9.6% weight loss
STEP 3	Intensive behavioral	-16.0% weight loss
SELECT	CV outcomes in obesity	20% MACE reduction

Off-Label Considerations

Ozempic for Weight Loss

Using Ozempic for weight loss (rather than Wegovy) has become common:

• Reasons: Insurance coverage, cost, availability
• Considerations: Off-label use, lower maximum dose than Wegovy
• Evidence: Same drug, but STEP trials specifically studied higher 2.4mg dose

Important Distinctions

Issue	Consideration
Insurance	Different coverage based on indication
Approval basis	Different trial programs
Prescriber intent	Should match approved indication

Safety Profile

Both products have identical safety profiles since they contain the same drug:

Common Side Effects

• Nausea, vomiting, diarrhea
• Abdominal pain, constipation
• Fatigue, dizziness

Serious Warnings

• Thyroid C-cell tumor risk (boxed warning)
• Pancreatitis
• Gallbladder disease
• Hypoglycemia (with insulin/sulfonylureas)
• Acute kidney injury

Cost and Access

Factor	Ozempic	Wegovy
Insurance Coverage	Often covered for T2D	Variable for obesity
Prior Authorization	Usually required	Often required
Supply Status	Intermittent shortages	Intermittent shortages
Generic Available	No	No

Summary

Ozempic and Wegovy are the same drug (semaglutide) with different:

• FDA-approved indications
• Maximum doses (2mg vs 2.4mg)
• Insurance coverage pathways
• Clinical trial evidence bases

The appropriate choice depends on the patient’s primary condition:

• Type 2 diabetes: Ozempic is the approved option
• Obesity/weight management: Wegovy is the approved option
• Both conditions: Either may be appropriate with provider guidance

---

This comparison is for educational purposes only. Medication decisions should be made with a healthcare provider.